2022
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez M, Honan E, Yang M, Chia P, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi M, Accordino M, Crew K, Hershman D, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer 2022, 4: 257-275. PMID: 36585452, PMCID: PMC9992270, DOI: 10.1038/s43018-022-00489-5.Peer-Reviewed Original ResearchConceptsBreast cancerDose-escalation clinical trialHDAC6 inhibitor ricolinostatMetastatic breast cancerPan-HDAC inhibitorsHistone deacetylaseHuman breast cancerIndividual histone deacetylaseSensitive cancer cellsNab-paclitaxelClinical responseMetastatic BCPredictive biomarkersClinical trialsClinical activityPreclinical studiesTumor typesHDAC6 activityCancer cellsHDAC6iAnticancer strategyPatientsRicolinostatCancerMultiple cohorts
2020
Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).
Fenn K, Singh V, Lee S, Cieremans D, Lassman A, Hershman D, Crew K, Accordino M, Trivedi M, Iwamoto F, Schultz R, Huynh L, Sales E, Fisher D, Mayer J, Kreisl T, Kalinsky K. Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF). Journal Of Clinical Oncology 2020, 38: 3567-3567. DOI: 10.1200/jco.2020.38.15_suppl.3567.Peer-Reviewed Original ResearchDiagnosis of LMLeptomeningeal metastasesCerebrospinal fluidLumbar punctureCSF cytologyNext-generation sequencingMedian age 56 yearsTime of LPSolid tumor diagnosisAge 56 yearsMetastatic breast cancerBreast cancer CTCsPeripheral blood samplesBreast cancer-related genesSomatic mutationsEvaluable ptsCNS lymphomaER statusHER2 statusBreast cancerStandard cytologyMetastatic therapyBlood samplesCSF samplesActionable mutations